Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy with or without nivolumab and BMS-986205 for muscle-invasive bladder cancer
2017-004692-31Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab, linrodostat, gemcitabine and cisplatin in bladder cancer and muscle-invasive bladder cancer (MIBC) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Pathological complete response rate. Started Aug 2018; status: active.
02
Drugs
03
Conditions
bladder cancermuscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on 2017-004692-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004692-31.